diagnostic and clinical impact of the revised definition of light chain mgus
Published 1 month ago • 79 plays • Length 1:38Download video MP4
Download video MP3
Similar videos
-
2:19
hematology in focus: mgus with clinical significance
-
1:55
quantifying biomarkers on lambda amyloidogenic light chains to diagnose al amyloidosis
-
1:41
an overview of the mds diagnosis pathway
-
2:20
ebmt diagnostic criteria for tma post-allosct and the role of complement activation
-
2:19
using ai to predict light chain amyloidosis in patients with mgus and smm
-
5:52
identifying mgus-like phenotype in multiple myeloma and light-chain amyloidosis
-
1:56
light chain glycosylation provides diagnostic clues in cad
-
1:32
the importance of cytogenetics and molecular profiling for accurate aml/mds diagnosis
-
1:34:31
antibody detection & identification
-
5:30
why is myeloma hard to treat? what is meant by a signaling pathway?
-
14:06
interpreting myeloma tests- case studies
-
3:26
the risk of thrombotic events in patients with mgus: an analysis from the istopmm trial
-
2:47
istopmm analysis results: autoimmune diseases are not associated with mgus
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
3:10
the role of ngs in mds diagnosis
-
2:33
what can artificial intelligence bring to the diagnosis and management of mds?
-
1:17
diagnosing rt and identifying patients at risk using ngs and molecular cytogenetic analysis
-
2:01
updates in mds diagnosis and prognosis with the ipss-m: personalized medicine in 2023
-
2:24
the importance of molecular testing in multiple myeloma and how this may impact future treatment
-
5:14
current status & updates in the management of al amyloidosis
-
0:41
improving risk stratification models for patients with mgus and smoldering myeloma
-
1:26
next-generation diagnostic and prognostic approaches in multiple myeloma